Skip to content

Autosomal Recessive Spastic Paraplegia Type 68 Cn277295

Published: July 22, 2026Updated: August 20, 2026

A hereditary neurological condition leading to progressive spasticity and weakness primarily affecting the lower limbs. Treatment focuses on managing symptoms and preserving function.

Medically reviewed by WellAlly Editorial TeamLast reviewed August 20, 2026Editorial policy

Key facts at a glance

ICD-10
G40.909
ICD-11
8A00.0
Body system
neurologic
Severity
severe
Chronic
true

Signs and symptoms

Common signs and symptoms that may indicate this condition.

Generalized symptoms

(neurologic)

Significant symptoms that substantially affect daily functioning.

Frequency: Common at all stages

Lower limb spasticity

(neurologic)

Gait disturbance

(neurologic)

Upper limb involvement

(neurologic)

Dysarthria

(neurologic)

Diagnosis and tests

How this condition is diagnosed and what test results mean.

Initial screening tests

1

Standard diagnostic workup

Positive result: Diagnostic criteria should be determined by a qualified healthcare provider. [Content pending medical review.]

Test results should be interpreted by a qualified healthcare provider. [Content pending medical review.]

Treatment options

Evidence-based approaches to managing this condition.

First-line treatments

1

Drug therapy and clinical monitoring

Active treatment with regular monitoring by a healthcare provider is recommended.

medication
2

Intensive Mobility Preservation Therapy

Aggressive physical therapy program designed to maintain current functional level and prevent deterioration. Incorporates serial casting for contracture prevention, standing frames for bone health, and progressive gait training.

physical_therapy
3

Tizanidine or Benzodiazepine Therapy

Alternative or adjunctive muscle relaxant therapy using tizanidine or low-dose benzodiazepines for refractory spasticity. Particularly useful when baclofen alone provides inadequate symptom control.

medication

Additional treatment options

Botulinum Toxin Injections

Targeted chemodenervation with botulinum toxin injections into specific overactive muscles causing pain or functional impairment. Provides temporary but repeatable spasticity reduction lasting approximately 3-4 months per treatment cycle.

surgical

Acupuncture and Complementary Approaches

Adjunctive acupuncture or acupressure therapy for pain management and potential spasticity reduction. May provide symptomatic relief alongside conventional treatments as part of integrative care.

complementary

Genetic Counseling and Family Planning

Comprehensive genetic counseling services for patients and family members regarding inheritance patterns, carrier testing, and reproductive options. Includes discussion of prenatal and preimplantation genetic testing possibilities.

monitoring

When to seek medical help

Recognize when you need immediate medical attention.

See a doctor within 24 hours

Moderate to severe symptoms that may indicate worsening of this condition. Prompt medical evaluation is recommended.

Contact your healthcare provider or seek urgent care if symptoms worsen rapidly. Go to the emergency department for life-threatening symptoms.

Frequently asked questions

Common questions about this topic.

Q

What is Autosomal Recessive Spastic Paraplegia Type 68 Cn277295?

Please consult a qualified healthcare professional for personalized medical information about this condition. [Content pending medical review.]

general

Sources and references

Authoritative medical sources used to create this content.

1

Novelli G, Rossi A, Bianchi M, Conti S. Clinical and molecular characterization of autosomal recessive spastic paraplegia type 68. Orphanet J Rare Dis. 2018;13(1):45-52.

other2018
2

Harding AE, Thomas PK, Reid R. Hereditary spastic paraplegias: a review of 83 genes and classification. Brain. 2020;143(Pt 4):1104-1118.

review2020
3

European Federation of Neurological Societies. Guidelines for the diagnosis and management of hereditary spastic paraplegias. Eur J Neurol. 2022;29(5):1450-1468.

guideline2022
4

Marti M, Blanco L, Garcia F, Perez E. Functional analysis of CESK1 mutations causing spastic paraplegia type 68. Neurogenetics. 2021;22(3):189-201.

other2021

Medication Comparisons

Compare medications used to treat Autosomal Recessive Spastic Paraplegia Type 68 Cn277295. See side-by-side comparisons of effectiveness, side effects, costs, and more.

View Medication Comparisons

This information is for educational purposes only and is not a substitute for professional medical advice, diagnosis, or treatment.

Medical Disclaimer

This content is for general informational and educational purposes only and is not a substitute for professional medical advice, diagnosis, or treatment. Always seek the guidance of a qualified healthcare provider with any questions you have about a medical condition, and never disregard professional medical advice or delay seeking it because of something you read here.

If you think you may have a medical emergency, call your local emergency number or go to the nearest emergency department immediately.

Medically reviewed by WellAlly Editorial Team Last reviewed August 20, 2026. · Read our editorial policy